Navigation Links
Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
Date:9/10/2013

SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has secured an option to an exclusive license for the worldwide rights to Biomiga Diagnostics' (Biomiga) proprietary therapeutic drug monitoring (TDM) device for paclitaxel products. The license and option agreement allows Sorrento to utilize the TDM device for the clinical development of individualized dosing regimens of Sorrento's late-stage compound, Cynviloq™ (paclitaxel polymeric micelle). Sorrento can exercise the option for exclusive rights to paclitaxel monitoring products and exclusive commercial supply by Biomiga upon the payment of $1 million within 30 days of the TDM device being ready for human clinical trials with Cynviloq.

Successful development of an oncology TDM program at the point-of-care may change the way cancer patients are treated. Biomiga's TDM device in development is intended to provide a point-of-care measurement of patient paclitaxel blood levels during chemotherapy treatment, potentially maximizing anti-tumor responses while minimizing toxicity. Paclitaxel chemotherapy treatment exhibits a narrow therapeutic window with a high variation in blood levels.

"This transaction reflects the forward-looking culture at Sorrento as we strive to become an innovator and leader in cancer therapy. Biomiga's TDM device may enable us to develop and deliver a potentially advantageous paclitaxel product for patients by establishing a new paradigm for chemotherapy," said Henry Ji, Ph.D., President and CEO of Sorrento.

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Completes IgDraSol Merger
2. Sorrento Therapeutics to Present at Two Healthcare Conferences
3. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
4. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
5. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
6. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
7. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
8. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
9. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
10. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
11. Sorrento Therapeutics Awarded Third Phase I STTR Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  Parnell Pharmaceuticals Holdings Ltd announces the ... added to Parnell,s already extensive pipeline through a ... biotechnology company. The compounds now known as PAR ... bone regeneration and dermal regeneration, respectively. Parnell has ... the veterinary market with the potential to also ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July ... , Weltweite Exklusivlizenz der Universität ... Entwicklung von Tests auf SF3B1-Mutationen, einschließlich von ... Neuer Test weist Mutationen des SF3B1-Gens nach, ... einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Minn., Oct. 7 Prime Therapeutics (Prime) announces that it ... of Care. Wickersham will manage Prime,s Clinical and ... medical and pharmacy. In this role, he will be responsible ... breakthrough results for Prime and its clients. "Keeping ...
... MINNEAPOLIS, Oct. 7 Nonin Medical, Inc., a ... today the release of its second-generation wrist-worn pulse ... PureSAT® SpO2 technology, the WristOx2, Model 3150 is ... proven accuracy in the widest range of clinical ...
Cached Medicine Technology:Prime Therapeutics Hires Peter Wickersham, Senior Vice President Cost of Care 2Nonin Medical Announces Its Second-Generation Wrist-Worn Device for European Distribution: Delivering Reliability in the Widest Range of Patient Populations and Clinical Settings 2
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 The ... Family Fun Fest on Sunday, July 27 at Discovery ... franchises include Memorial, Copperfield, Katy, Pearland, Friendswood, Spring, The ... in The Heights. , “We’re thrilled to be ... year,” said Heather Belcher who owns the Sugarland-Missouri City ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... revealed that 39 percent of all children in the survey ... , The survey looked at 2,505 children during the years of ... four years of age. The final result was that about ... care. Many of these children were from lower-income families and were ...
(Date:7/25/2014)... 27,000 older adults on five continents found that nearly ... a simple test that measures how fast people walk ... positive for pre-dementia were twice as likely as others ... by scientists at Albert Einstein College of Medicine ... , was published online on July 16, 2014 in ...
(Date:7/25/2014)... News) -- Shift workers, especially men, may be at higher ... such schedules, a new study suggests. Also at special ... schedule, with shifts moving around at various times of the ... one expert, Dr. Alan Manevitz, a clinical psychiatrist at Lenox ... known that working shifts disrupts many key body chemicals, creating ...
(Date:7/25/2014)... (ASA) today announced the launch of its ASA ... initiative designed to improve the patient experience before, ... leading health care organizations from across the country ... for the first time at the ASA,s PSH ... , The PSH collaborative participants will create a ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3
... HealthDay Reporter , MONDAY, Sept. 5 (HealthDay ... may be creeping into the U.S. blood supply and ... researchers report. , Babesiosis is a parasitic infection that ... blood transfusion. Symptoms range from mild flu-like symptoms to ...
... University,s Mailman School of Public Health heightens concerns over ... of ubiquitous chemicals known as phthalates. Phthalates are a ... endocrine system, and are widely used in consumer products ... shampoos. Recent studies of school-age children have provided ...
... PAUL, Minn. Psychogenic non-epileptic seizures may go undiagnosed for much ... study published in the September 6, 2011, print issue of ... of Neurology. This type of seizure is different from seizures ... origin. "People with psychogenic seizures are often diagnosed with ...
... in a study published in the Archives of General Psychiatry ... serotonin (a brain chemical related to mood), may serve as ... stress disorder (PTSD) following a trauma. "One of ... at risk for developing the disorder following a trauma, while ...
... Reporter , MONDAY, Sept. 5 (HealthDay News) -- Growing ... vaccines, which could indicate that resistance to children,s inoculations ... getting better, but we still have a fair way ... immunization services division at the National Center for Immunization ...
... , MONDAY, Sept. 5 (HealthDay News) - Rudeness ... the workplace, a new study shows. Researchers from Baylor ... that stress home with them, which can have negative effects ... jobs. The researchers explained that when employees go home ...
Cached Medicine News:Health News:Tick-borne Illness May Lurk in Blood Supply 2Health News:Tick-borne Illness May Lurk in Blood Supply 3Health News:Prenatal exposure to phthalates linked to decreased mental and motor development 2Health News:Non-epileptic seizures may be misdiagnosed longer in veterans 2Health News:The search for predictors of risk for PTSD 2Health News:More U.S. 'Tweens' Getting Recommended Vaccines 2Health News:More U.S. 'Tweens' Getting Recommended Vaccines 3Health News:Boorish Co-Workers Can Damage Your Home Life 2
... Diagnostic Workstation Software offers a complete ... digitally stores many different diagnostic tests ... open-architecture products in mind, our software ... (using ActiveX controls), networking, central database ...
... is engineered to set a new standard ... is enter the patient demographics, select auto ... Windows based system uses the latest in ... versatility of the IQmark Holter algorithm. Simple, ...
... remarkable skin Transformation in less than an hour ... peels or other superficial procedures, the Obagi Blue ... yours. Based on your patients' particular skin needs, ... Acid (TCA) peels and number of coats applied. ...
... Smoothie is deliciously refreshing scrub ... the use of a gentle ... exfoliate the skin to restore ... irritation. This light chemical peel ...
Medicine Products: